Pricing Log in Create free account

Candel Therapeutics, Inc. (CADL) vs Prime Medicine, Inc. (PRME)

Candel Therapeutics, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Prime Medicine, Inc. is the larger, with a market value of $779.9M against $705.5M — 1.1× the size. Candel Therapeutics, Inc. grew revenue faster over the last twelve months: 0.00% against −17.9%. Candel Therapeutics, Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Candel Therapeutics, Inc. leads on 11 and Prime Medicine, Inc. on 5.

Valuation

Metric CADL PRME Biotechnology median
P/E n/m n/m 11.58
P/S 5,473.85 186.67 9.61
P/B 5.42 19.10 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 4,277.78 163.33 9.43
Earnings yield (15.28%) (25.74%) (32.28%)
Free cash flow yield (8.37%) (20.63%) (22.27%)

Profitability

Metric CADL PRME Biotechnology median
Gross margin 0.00% 100.00% 68.81%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (81.84%) (373.29%) (50.30%)
Return on assets (56.37%) (71.16%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CADL PRME Biotechnology median
Revenue growth (TTM) 0.00% (17.90%) 6.78%
EPS growth (last fiscal year) 58.62% 18.18% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL PRME Biotechnology median
Debt to equity 0.38 0.00 0.00
Current ratio 16.09 3.05 4.74
Net debt to EBITDA 1.53 0.88 1.01

Dividend

Metric CADL PRME Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CADL PRME Biotechnology median
Market cap 705.50m 779.92m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack